Injections of Glutamic Acid Decarboxylase (GAD) for LADA Type of Diabetes

Phase 2 Completed 14 enrolled Norwegian University of Science and Technology Diamyd Medical AB · collab Karolinska Institutet · collab Linkoeping University · collab St. Olavs Hospital · collab

NaSingle-groupOpen-labelTreatment

Summary

This study will evaluate the effects of 3 intra-nodal injections of GAD-alum (Diamyd), together with oral vitamin D supplementation. Safety and feasibility of the treatment will be evaluated and also effects on the immune system and on the preservation of endogenous insulin production.

Timeline

Start: 2020-03-02
Primary completion: 2022-05-05
Completion: 2022-05-05

Publications

Background Hals IK, Fiskvik Fleiner H, Reimers N, Astor MC, Filipsson K, Ma Z, Grill V, Bjorklund A. Investigating optimal beta-cell-preserving treatment in latent autoimmune diabetes in adults: Results from a 21-month randomized trial. Diabetes Obes Metab. 2019 Oct;21(10):2219-2227. doi: 10.1111/dom.13797. Epub 2019 Jun 19.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	GLUTAMATE DECARBOXYLASE 2	Vaccine	4 ug	Other
Background	Vitamin D	Other / unclassified	2000 iu	Oral

Injections of Glutamic Acid Decarboxylase (GAD) for LADA Type of Diabetes

Summary

Timeline

Publications

Drugs

Indications